Core Insights - Xunfei Medical Technology reported a revenue of 734 million yuan for the year 2024, representing a year-on-year growth of 32.0% [1] - The company narrowed its net loss to 133 million yuan, an improvement of 8.5% compared to 2023 [1] - The integration of AI large models with the medical industry has driven rapid revenue growth in specific medical segments, maintaining a high gross profit margin [1] Revenue Breakdown - Revenue from primary healthcare services reached 237 million yuan, accounting for 32.3% of total revenue [1] - Hospital services generated 132 million yuan, representing 18% of total revenue [1] - Revenue from regional management platform solutions was 154 million yuan, making up 20.9% of total revenue [1] - Patient services contributed 211 million yuan, which is 28.8% of total revenue [1] Profitability Metrics - The gross profit margin for Xunfei Medical Technology was 55.1%, a decrease of 1.5 percentage points year-on-year [1] - The decline in gross margin is attributed to technical upgrades of hospital service products based on medical large models, which affected initial market promotion revenues [1] - The company anticipates rapid revenue growth and an improvement in gross margin levels moving forward [1] R&D Investment - Total R&D investment, including R&D expenses, amounted to 297 million yuan, with core technology R&D spending increasing by 13.2% year-on-year [2] - R&D expenditures represented 40.4% of total revenue [2] Future Developments - On March 3, 2025, the company plans to launch the Spark Medical Large Model X1, which aims to significantly reduce medical hallucinations and enhance reasoning accuracy, professionalism, and interpretability in medical scenarios [2] - The company noted that the costs associated with large model training and reasoning are decreasing rapidly, indicating a new phase of rapid development for the medical AI industry [2] - The medical industry demands high standards for AI technology due to its seriousness, safety, and the need for continuous integration with medical practices [2]
讯飞医疗科技发布上市后首份财报：营收同比增长超三成 净亏损收窄8.5%